

ASX Announcement

Date of AGM and Closing Date for Director Nominations

9 October 2023 – Race Oncology Limited (“Race”) advises, in accordance with ASX Listing Rule 3.13.1, that its Annual General Meeting will be held at 12.00 pm AEDT on Monday, 27 November 2023 at the Dixon Room, State Library NSW, 1 Shakespeare Place, Sydney, New South Wales.

An item of business at the AGM will be the re-election and appointment of Directors. In accordance with clause 15.3 of the Company’s Constitution, the closing date for the receipt of nominations from persons wishing to be considered for election as a Director is Monday, 16 October 2023.

Any nominations must be received by the Company in writing by no later than 5.00 pm AEDT on Monday, 16 October 2023.

-ENDS

About Race Oncology (ASX: RAC)

Race Oncology (ASX: RAC) is an ASX-listed clinical stage, global biotechnology company with a dedicated mission to be at the heart of cancer care.

Race’s lead asset, bisantrene, is a small molecule anthracene chemotherapeutic. Bisantrene has a unique and rich clinical history with demonstrated therapeutic benefits in both adult and paediatric patients, a well characterised safety profile, and compelling clinical data demonstrating an anti-cancer effect and less cardiotoxicity than other comparable agents.

Race is developing bisantrene to address the high unmet need of patients across multiple oncology indications, with an initial focus on metastatic breast cancer (lead indication) and acute myeloid leukaemia (AML) exploring anti-cancer plus cardio-protection in synergy with known standards of care.

As part of its clinical and preclinical programs, Race is investigating the effect of bisantrene on the m⁶A RNA pathway, following independent research by the City of Hope identifying bisantrene as a potent inhibitor of FTO (Fat mass and obesity-associated protein). Dysregulation of the m⁶A RNA pathway has been described in numerous peer reviewed studies to be a driver of a diverse range of cancers.

Race Oncology is in collaboration with City of Hope, MD Anderson, Sheba City of Health and UNC School of Medicine, and is actively exploring partnerships, licence agreements or a commercial merger and acquisition to accelerate access to bisantrene for patients with cancer across the world.

Learn more at www.raceoncology.com

If you have any questions on this announcement or any past Race Oncology announcements, please go to the Interactive Announcements page in our Investor Hub <https://announcements.raceoncology.com>

Race encourages all investors to go paperless by registering their details with the Company’s share registry, Automic Registry Services, at www.automicgroup.com.au.

Release authorised by:

The Race Oncology Board of Directors
info@raceoncology.com

Media contact:

Jane Lowe +61 411 117 774
jane.lowe@irdepartment.com.au